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Industry working with physicians through
professional medical associations
Michael C. Dalsing, MD, Indianapolis, Ind
The physician/surgeon’s interactions with industry have come under scrutiny in recent years for several reasons.
Although some think that the professional medical association or society may provide an avenue to allow such interactions
with less risk, there are concerns and challenges for such organizations as it relates to ethical and professional norms of
their members. This is one surgeon’s review of some pertinent information regarding what the professional medical
society provides to its members and what role industry plays in the society’s ability to provide these benefits. There is an
exploration of the risks involved and practical methods to control inherent conflicts of interest involved in this
interaction. (J Vasc Surg 2011;54:41S-6S.)
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aIn the public’s impression, much of the focus of the
physician’s or surgeon’s interaction with industry has fo-
cused on the violation of federal antifraud statutes by
certain practitioners who were paid excessive “consultant
fees” as potential kickbacks for using specific devices in their
patients.1 As a result, the issue of how industry works with
the medical community has come under scrutiny. Medical
associations and surgical societies provide a perceived ave-
nue of “at arm’s length” dealings with industry less likely to
be viewed as an antitrust issue, but even these relationships
are being scrutinized.2-7 A review of what the professional
medical society provides its members, the role industry has
in the society’s ability to provide membership benefits, the
risks involved, and methods to control inherent conflicts of
interest are the subject of this article.
MEMBER BENEFITS PROVIDED BY THE
PROFESSIONAL MEDICAL ASSOCIATION
Local, regional, national, and international professional
medical societies provide many potential benefits but com-
mon to all is the desire to provide an educational experience
for the members. As such, the societies shape clinical prac-
tice and affect patient care in a most direct manner. For the
local and regional societies, this often means an annual
meeting surrounded by an educational program. In some
cases, the regional, national, and international societies may
provide adjunctive educational experience outside of the
annual meeting. Some of these courses involve education
on emerging new technologies.8-10 The choice of content,
presenters, and moderators does influence a physician’s
decision regarding patient care. Generally, these experi-
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doi:10.1016/j.jvs.2011.04.068nces are structured to provide continuing medical educa-
ion (CME) credits required as part of a surgeon’s local
redentialing or more recently for Maintenance of Certifi-
ation (MOC).
Most major professional medical societies have devel-
ped a professional journal to publish the latest research
nd clinical information pertinent to the society’s and its
embers’ needs. The content of these journals are gener-
lly peer-reviewed and certainly influence the care of our
atients. The major journal can be augmented by other
ublications sponsored by the society, for example for the
ociety for Vascular Surgery there is Vascular Specialist and
VS Pulse with the major journal being the Journal of
ascular Surgery. The society may also offer on-line up-
o-date information on clinical trials, research opportunities,
nd current medical news.8,10,11 Others have published
ooks or standardized courses that provide information on
atient care and influence those members who utilize this
nformation. Some examples are the Handbook of Venous
isorders: Third Edition, Vascular Education and Self-
ssessment Program (VESAP), Advanced Trauma Life
upport Course (ATLS) or Surgical Education, and Self-
ssessment Program (SESAP).8,10,11
Practice guidelines have long been a function of medi-
al associations. One prime example is the “Use of Antico-
gulation” revised periodically and published in CHEST.12
he Society for Vascular Surgery has recently entered this
rena with a very structured evidence-based approach to
he treatment of some select vascular disorders. In addition,
he members can use patient educational articles on vascu-
ar diseases and treatments developed by the society.8
There are research grants and scholarships offered by
edical societies to help the members to advance the basic
cience and clinical knowledge pertinent to the goals of the
embers. Certainly, the research proposals chosen will
efine the field for the future.
The Professional Medical Society provides some valida-
ion of the member’s connection with the care of patients
ith a particular problem. For example, the Society for
ascular Surgery (SVS) notes that membership provides
ffiliation with the largest professional association in the
orld representing vascular surgeons and the prestige of
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September Supplement 201142S Dalsing et alusing the SVS logo in one’s practice. Members have the
opportunity to serve on committees and councils that do
impact the direction of the society. Participation in an
on-line physician referral service and access to branding
initiatives to develop one’s practice, including free down-
loading of patient educational materials, press releases and
interview guidelines for media promotion, screening mate-
rials, and guidelines to offer screenings are additional ben-
efits.8 Most of these services are available through the
society’s Web site which in itself is a membership benefit.
There are societies that provide clinical databases for
the use of their members.11
There is also a legislative aspect to societal membership
since many medical associations have a professional govern-
ment affairs staff working on the members’ behalf to impact
federal legislative and regulatory processes directly related
to the member’s practice and patients.8,10 The society often
provides an advocacy support with a convenient on-line
method to interface with federal government representa-
tives.
Some larger national professional medical associations
have even ventured into insurance and investment products
as well as liaison with multiple organizations with some
having an international interchange as well.8,10,11
For those of us who remember the humble beginnings
of some of our societies, this laundry list of benefits is a far
cry from the annual meeting for sharing of new knowledge
and camaraderie envisioned by the founding fathers.
INDUSTRY’S CONTRIBUTION TO
PROFESSIONAL MEDICAL ASSOCIATIONS
Industry has become increasingly involved with the
education of health care providers, including surgeons,
through the support of medical professional associations/
societies. Unlike academic medical centers that have several
avenues to support their missions, professional societies
generally gain support for their goals by membership dues
and monies generated from the annual meeting and other
educational programs. It is readily apparent that this sup-
port is inadequate to realize the many other activities
expected of a modern professional society or even the
educational mission of the society.7,13 In the early to mid
years of the last decade, industry funded 50% to 60% of all
CME activities provided by nationally accredited CME
providers and with the economic turndown, this is likely a
low estimate of support today.14,15 In fact, in 2006, physi-
cian member organizations received 58.5% of their CME
income from commercial support and advertising/exhib-
its.16
Industry has been willing to provide large sums of
money to support patient-education materials, the most
recent being a partnership between the American Academy
of Family Physicians (AAFP) and Coca-Cola Corporation
to support patient education materials on obesity preven-
tion.6
Professional medical associations have endorsed indus-
trial products to provide financial support for their many
missions.17,18 Whether the superiority of the products en- oorsed was supported by evidence was generally not a point
f elaboration.
The ability of our members to engage in research is
nhanced by industry with which the medical societies
artner to provide the research monies. Industry funds
early 60% of all biomedical research performed in the
nited States with pharmaceuticals providing 30%, bio-
echnology firms another 20%, and medical device compa-
ies about 10%.19 In 2004, this investment accounted for
ore than 50% of the clinical research being conducted in
he United States.19 This may become an even larger
omponent of the research funding as the federal govern-
ent decreases its commitment to basic and clinical re-
earch.20
It has not been unusual for industry to fund graduate
edical education fellowships. In fact, in the summer of
008 after an intensive investigation with prosecution of
everal orthopedic manufacturers by the Department
f Justice, many orthopedic fellowships were in danger of
ancellation due to lack of funding.1 The American College
f Cardiology has been involved with a joint industry
enture to fund adult cardiology fellowships.4 The Ameri-
an Academy of Dermatology Board of Directors appar-
ntly acquired partial funding from industry for several new
ermatology positions with the goal of increasing the sup-
ly of dermatologists.21
Indirect support and potential influence by industry on
he development of practice guidelines has occurred by
irtue of the fact that panel members have benefited from
esearch support and/or payment of activities on advisory
oards or as consultants.22,23 There has also been direct
nancial support for the development of guidelines by
ompanies with a vested interest.22
Industry supports our medical journals through adver-
isements, purchase of articles and sometimes entire issues,
nd occasionally by supporting supplemental issues. The
rofits can be so impressive that a journal can be sent free to
hysicians, and the journal and its sponsor can reap huge
rofits.24 This can be especially true for supplements
unded by a single company and dealing with one drug as
n example.24
Some of the available databases sponsored by medical
ocieties are funded in part or completely by industrial
upport allowing free access for the members.25
During the early 2000s, some specialty physician med-
cal associations had over 50% of their operating budget
rovided by commercial support and exhibit fees, and in a
eriod of economic stress, this may have escalated in the last
everal years.14 In 2008, 24% of the operating budget of the
merican Academy of Orthopedic Surgeons and 29.5% of
he operating budget of the American Orthopedic Associ-
tion came from orthopedic industry, which had not de-
reased from prior years.1
I believe it is safe to say that industry provides a signif-
cant contribution to medical associations which allows
heir members to be provided with services they have come
o expect. Overall, I would venture that 30% to 50% of the
perating budget of most professional medical societies,
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Volume 54, Number 18S Dalsing et al 43Sboth medical and surgical specialties, is garnished somehow
from a relationship with industry. The societal goals and
objectives requiring this amount of funding are all com-
mendable and desirable, but the question arises whether
there is some trade-off or compromise of goals when the
funding is from a for-profit enterprise.
THE RISKS OF PROFESSIONAL MEDICAL
ASSOCIATION/INDUSTRIAL INTERACTIONS
The Professional Medical Society and Industry groups
have different norms by which they must live. This differ-
ence is exemplified by what people view as professionalism
and commercialism. Commercialism is seen as buyers and
sellers acting in their own interest. Companies are in busi-
ness and their duty is to their stockholders to make money.
For pharmaceutical and medical device companies, this
means selling products to our patients.4 Since we are the
gatekeepers, any access, influence, and gratitude to and
from the physician/surgeon are considered a good invest-
ment. Industry has an interest in supporting medical asso-
ciations to gain favor with the leadership and board mem-
bers who decide the program, sit on guideline committees,
and generally determine the direction of the society.4 The
people in companies often are very compassionate in pro-
viding our patients the best that they can, but the business
aspects are still their prime duties. I believe Sieghart may
have expressed it best when he noted that in a professional
relationship, altruism is paramount and self-interest has no
place, which is a striking difference from the rules of con-
duct applicable to every other market supplying goods and
services.26
The professional medical society has an ethical obliga-
tion to its members, our patients, and society. The profes-
sional medical society is an extension of its members of
which its leaders are a part, all of whom are subject to the
professional norm. The professional norm involves recog-
nizing certain obligations for the privileges society has
granted each. Such obligations include the responsibility to
gain and use medical knowledge with integrity, in the best
interest of the patient and free a self-serving interest.27-29
Some would contend that interest is not a sufficiently
strong term, but rather it is our duty to best serve our
patients.4,30 It is the duty of the medical society to provide
unbiased education and services for the members and by
extension, the members’ patients. By the education pro-
vided, the practice guidelines endorsed, and the ethical
norms espoused by the medical society, the practice of
medicine must be enhanced and optimized. The public
agenda of the professional medical association advocates for
the best interest of their members, for patients and for
society in general.3 The professional medical society repre-
sents expertise and authority for those in and out of the
medical arena.2,3 The professional medical society is the
“public face” for the specialty and the profession. This
public impression places much power in the medical society
but also comes with an obligation to conform to the
professional norm. cSince the professional medical society is held in such
steem by the public, any situation that potentially com-
romises clinical decision making, adversely affects health
are delivery or undermines the reputation of the profes-
ion is detrimental.3,31 Any real or perceived commercial
ias can affect membership enrollment, credibility as a
ource of continuing medical education, jeopardize certifi-
ation by the Accreditation Committee for Continuing
edical Education (ACCME), and diminish effectiveness
s a “professional voice” to the public.2 There is no ques-
ion that the medical profession is held to a different
tandard and the medical society must recognize, and then
ealize, its missions within this framework. When the med-
cal society steps over these bounds, either perceived or
eal, the trust placed in the profession comes into ques-
ion. There are examples in which a professional medical
ssociation/industrial interaction has caused concern and
ere detrimental to the reputation of the medical profes-
ional association; so the risk is real.
There are some aspects of interacting with industry that
ight be more challenging for professional organizations
han individuals since industry is so visible at societal func-
ions. At the annual meeting, industry has banners, booths,
nd industrial-sponsored symposia. This visibility can be
erceived as endorsement.2 So the professional society,
hen considering conflict of interest, must consider a wide
ange of issues from sponsorship to how to address indus-
rial symposia held in close proximity to the annual meet-
ng.
The funding of continuing medical education by
ndustry is extensive, and many stakeholders in the dis-
emination of unbiased information have voiced con-
erns.16,32 A joint project between a professional medi-
al society and industry to produce a patient educational
roduct has generated significant controversy likely be-
ause of the funding amount and the specific industry
nvolved.6 Endorsement by a professional medical soci-
ty, especially when a fee is paid, is often seen as selling
ne’s integrity to the highest bidder.17,18 Industrial-
upported research tends to favor the industrial product
n a statistical sense that stresses a need for vigilance
hen entering into such an arrangement.33 Certainly,
tatements made by professional medical societies re-
arding the results of research, which may favor one
ndustrial product, particularly when that society is ben-
fited by its association with that industry and when the
otential conflict of interest or interaction with industry
ad not been properly disclosed, can result in a harsh
esponse from the public.4 The integrity of the society
as also been called into question when industry ap-
eared to have significant influence over societal spon-
ored fellowships, guidelines, journals, and other efforts
hat were being supported by industry.4,21-23 It appears
hat essentially all joint ventures between professional
edical/surgical societies and industry have generatedontroversy when impropriety was perceived.
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INTEREST
There are basically two ways to address conflict-of-
interest issues. One strategy is to continue the activity but
attempt to manage the risk or, alternatively, one can divest
oneself of the risk by ceasing the activity. Certainly there has
been a trend closer to a divestment rather than a manage-
ment strategy by a diverse group, especially those address-
ing the ethic issues.2,4,5 However, many find that a middle
road is more practical for the survival of the medical society
and the control of conflict of interest.2,3 There is one area in
which essentially all authors believe that a joint venture with
physicians, surgeons, and their organizations with industry
is desirable and required. The expertise of each is needed to
bring a novel pharmaceutical or medical device to the
patient.4,34,35 But even this joint venture must be well-
defined, properly valued with deliverable work, and must
not step into the area of marketing or sales.
So what has the community of professional medical
societies done to address conflict of interest? Some have
formulated a conflict-of-interest statement for all members,
including the leadership by default.36 Some have published
conflict-of-interest statements that include statements spe-
cifically addressing how a member should conduct him/her
self when a leader within the society.37 Others have conflict-
of-interest policies for the leadership of the society.38
The most advanced project to address conflict-of-interest
policies for professional medical societies is through the
Council of Medical Specialty Societies, which published a
voluntary “Code of Interactions with For-Profit Health
Sector” and has 13 medical societies formally adapting the
code with commitment to full implementation.39,40 The
approach is much like the Advanced Medical Technology
Association and Pharmaceutical Research and Manufactur-
ers of America codes of interaction with health care provid-
ers formulated, however, for their device-related or phar-
maceutical industrial members.41,42 The full code of
interaction is a 25-page document that had broad-based
member input and is available at the Council of Medical
Specialty Societies Web site.43 There are 10 principles for
“Interaction.” Independence is the first principle, stating
that all societal activities will be free of company influence
and that all societal/industry interactions will be guided by
a high-level group (eg, Ethics Committee, Conflict of
Interest Committee). Possibly the most controversial com-
ponent of the principle of independence is that no key
society leader, defined as those in the presidential line of
succession, chief executive officer and editor(s)-in-chief of
the society journal(s), may have direct financial relationship
with companies during his or her term of service. In addi-
tion, the society will have written agreements with compa-
nies for educational grants, corporate sponsorship, charita-
ble contributions, business transactions, and support of
research grants. Transparency is the second principle and
involves making available to the members and public, the
society conflict of interest policies/forms and disclosing
company support. There will also be written disclosure iolicies for key leaders, board members, committee mem-
ers, and others directly serving the society. The financial
nd uncompensated relationships of key leaders and board
embers will be available to the members and the public.
he third principle regards accepting charitable contribu-
ions that is appropriate if it aligns with the societal mission
nd is free of company influence. In addition, policies for
onsistent and appropriate recognition of donors are to be
dopted. The fourth principle addresses accepting corpo-
ate sponsorship that is acceptable if it aligns with the
ociety mission, involves reasonable efforts to seek multiple
ponsors, and does not allow for company logos on “gifts.”
f used for support of data registries, corporate sponsors
annot participate in direct registry management. The fifth
rinciple regards societal meetings and has four subcatego-
ies. GME grants must comply with ACCME standards for
ommercial support. The society must have full control
ver the entire program from topics to speaker selection
llowing presentation of a balanced educational program
ddressing areas of knowledge gaps. The society itself will
ddress any COI issues. All CME-accredited satellite sym-
osia must comply with ACCME standards and must be
learly distinguished from societal CME activities. Non-
ME programs must be clearly distinguished from societal
rograms. The society will adopt written policies governing
xhibits and the conduct of the exhibitors during the
eeting. Exhibit booths should be outside of attendees’
bligate route to societal CME activities, and no key leader
hould participate in company promotional/marketing
vents. The sixth principle deals with awarding of research
rants. Again, independence is critical in that companies
annot influence the selection of recipients, meet with the
ecipients, receive intellectual property rights or royalties
esulting from the research, or influence the results or
anuscripts resulting from the research. Societal research
upported by corporate funding requires disclosure and
ndependence of all aspects of the research. Clinical practice
uidelines are the seventh topic and must be evidence-
ased, free of company influence and not directly sup-
orted by companies during development or publication.
here are many safeguards needed in the generation of
ractice guidelines, including disclosure of relevant rela-
ionships prior to and updated during the development
rocess. Any conflicts must be resolved by the society prior
o panelist involvement. The majority of guideline devel-
pment panel members must be free of conflict of interest
elevant to the guideline and the panel chair must be free of
onflict during, and for 1 year after, the guideline publica-
ion. The guideline recommendations must go through
ultiple levels of review both within and outside the society
nd, when published, any conflicts of interest should be
isclosed with the publication. The entire process must be
ompletely devoid of corporate influence at all levels. Soci-
tal journals must have editorial independence from the
ociety and advertisers, all conflicts of interest must be
isclosed for published works, and “ghost-written” manu-
cripts prepared by or on behalf of a corporation is prohib-
ted. The society must adopt written policies setting stan-
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principle that stresses to the society the need for written
standards to prevent misuse, unintended use, modifica-
tions, or implied endorsement by the society of company
products or services. These principles use both the manage-
ment of conflict of interest and, in some cases, divestment
when seen as most needed to control conflict-of-interest
issues. Little is directly stated about the value of deliver-
ables, which is often the test of what task is being performed
for what goal, but it would be imagined that the written
policies should address some component of this issue.2,4
Maintaining independence in all societal activities, dis-
closure of all interactions especially by societal leadership,
and accepting grants not ear-marked by industry for a
particular individual or industry-inspired project are fine
principles of interaction. However, underlying all these
principles to manage conflict-of-interest risk is the knowl-
edge that “money speaks.”4 The problem is that none of us
see ourselves as affected by corporate influence, which
simply is not true.33,44,45 We, as individuals, and when
functioning within a professional medical society must re-
alize and react to the fears of our patients, the legal system,
and the federal government.3,4 We, as a professional med-
ical society, must not become so tied to industrial support
that the society cannot (or will not) function without that
support.3,5,6 Fearing the risk of sounding editorial, maybe
there should be some thought to decreasing our depen-
dence on industry by restricting overall support from indus-
try to no more than 25% of the societal budget as some have
suggested, and starting the weaning process.3
The rationale for principles regarding the professional
medical association interaction with industry have been pub-
lishedandsomearereferencedforreview.2-6,15,17,22-24,30,31,35
It is very important for professional medical societies to
address the issue of conflict of interest for the good of their
members and the public interest. We need viable profes-
sional medical societies, who will be our voice to the world
with the social trust required to make them effective advo-
cates for our patients and medicine in general.
CONCLUSION
The professional medical and surgical society interac-
tions with industry have come under scrutiny, as have all
physician/industry interactions. The interaction of the pro-
fessional medical society with industry has become more
entangled, as the societies have offered more and more
member-expected benefits. Industry likely funds 30% to
50% or more of most professional medical associations’
member benefits by supporting the annual meeting, CME
courses, fellowships, research, patient educational bro-
chures, and the list goes on. Industry is in business to
improve the shareholders’ profits. Physicians, and by exten-
sion our professional societies, are in the medical profession
with prime interest in the optimal care of their patients
unaffected by self-interest. Since the professional medical
society is the public face of our profession and directs many
of our professional decisions by virtue of education, publi-
cations, and practice guidelines in addition to other activi-ies, the issue of conflict of interest becomes a real concern
or members, patients, and other interested organizations.
ince public trust and the society’s integrity are so impor-
ant to the society’s advocacy for its members and our
atients, any real or perceived event that could call into
uestion the society’s duty to the public good is unaccept-
ble. As a result, methods to manage or divest conflict of
nterest with industry are being proposed and imple-
ented. Maintaining robust professional medical associa-
ions free of industrial influence over the core missions of
he society is the desire and goal of all these efforts.
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